Core One Labs Inc
CNSX:COOL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (7.3), the stock would be worth CA$0.15 (0% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7.3 | CA$0.15 |
0%
|
| 3-Year Average | 7.3 | CA$0.15 |
0%
|
| 5-Year Average | 11.5 | CA$0.23 |
+59%
|
| Industry Average | 1.5 | CA$0.03 |
-80%
|
| Country Average | 2.9 | CA$0.06 |
-60%
|
Forward P/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
C
|
Core One Labs Inc
CNSX:COOL
|
6.8m CAD | 7.3 | -0.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 12.5 | 39.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 5.6 | 25.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 4.7 | 27.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 4.8 | 19.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 4.2 | 14.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 3.7 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 2.4 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 2.4 | 16.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.4 |
| Median | 2.9 |
| 70th Percentile | 4.9 |
| Max | 15 623 917.6 |
Other Multiples
Core One Labs Inc
Glance View
Core One Labs, Inc. is a biotechnology company, which engages in the manufacture of cannabis-infused strips. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2011-08-17. The firm is focused on advancing psychedelic medicines to market through delivery systems and psychedelic assisted psychotherapy and active pharmaceutical ingredients (API) grade psilocybin manufacturing. Core One has developed its technology, thin film oral strip, which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining bioavailability. The firm also intends to develop and apply the technology to psychedelic compounds, such as psilocybin. Core One produce current Good Manufacturing Practice (cGMP) API grade psilocybin for use by pharmaceutical companies, API manufacturers and organizations conducting clinical trials, providing access to organizations. Core One also holds an interest in medical clinics, which maintain a combined database of approximately 275,000 patients.
